Dr Melissa E Cutcliffe, DPT | |
7414 Morrow Rd, Pavilion, NY 14525-9315 | |
(585) 409-6285 | |
Not Available |
Full Name | Dr Melissa E Cutcliffe |
---|---|
Gender | Female |
Speciality | Physical Therapist |
Location | 7414 Morrow Rd, Pavilion, New York |
Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1154618999 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
225100000X | Physical Therapist | 033734 (New York) | Primary |
Mailing Address | Practice Location Address |
---|---|
Dr Melissa E Cutcliffe, DPT 7414 Morrow Rd, Pavilion, NY 14525-9315 Ph: (585) 409-6285 | Dr Melissa E Cutcliffe, DPT 7414 Morrow Rd, Pavilion, NY 14525-9315 Ph: (585) 409-6285 |
News Archive
Women sexually abused in childhood and adolescence who suffer from depression and post-traumatic stress disorder benefit significantly from Interpersonal Psychotherapy-Trauma, according to a Rutgers researcher.
House Oversight and Government Reform Committee Chairman Darrell Issa, R-Calif., has raised questions about the implementation of a key part of the health law - the tax treatment of subsidies for low-income people to purchase health insurance.
Scientists at Albert Einstein College of Medicine of Yeshiva University have proposed a sweeping new theory of autism that suggests that the brains of people with autism are structurally normal but dysregulated, meaning symptoms of the disorder might be reversible.
Disease interventions, such as the use of insecticide-treated nets to prevent malaria and increased access to HIV treatment and prevention, have helped reduce the number of deaths among children younger than age five worldwide to 9.2 million in 2007, down from 9.7 million in 2006 and 12.7 million in 1990, according to a UNICEF report published Friday in the journal Lancet, Reuters reports (Kahn, Reuters, 9/12).
Pfizer Inc. today announced that the randomized Phase 2 trial [PALOMA-1] of palbociclib achieved its primary endpoint by demonstrating a statistically significant and clinically meaningful improvement in progression-free survival (PFS) for the combination of palbociclib and letrozole compared with letrozole alone in post-menopausal women with estrogen receptor positive (ER+), human epidermal growth factor receptor 2 negative (HER2-) locally advanced or newly diagnosed metastatic breast cancer.
› Verified 6 days ago